Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
12.5.2022 09:00:00 EEST | Business Wire | Press release
Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)
The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.
Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.
The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.
Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”
Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.
About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005724/en/
Contact information
Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com
Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veracode 2026 State of Software Security Report Reveals Four Out of Five Organizations Are Drowning in Security Debt24.2.2026 14:50:00 EET | Press release
Veracode, the global leader in application risk management, today released its 2026 State of Software Security Report, revealing the widening gap between how fast organizations build software and how fast they can secure it. The report found 82 percent of organizations now harbor security debt—an 11 percent increase from the prior year—and that 60 percent of those organizations have security debt defined as “critical,” representing accumulated vulnerabilities severe enough to cause catastrophic damage to an organization if exploited. The report recommends adopting a “Protect, Prioritize, and Prove” strategy to meaningfully reduce risk in 2026 and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224526703/en/ Fig. 1: Veracode State of Software Security Report 2025 vs 2026 YoY Change Now in its 16th annual edition, Veracode’s flagship report analyzed 1.6 million unique applications spanning enterprises, commercial sof
Canoga Perkins and Druid Deliver FRER-Enabled Resilience for Mission-Critical Private 5G Networks24.2.2026 14:00:00 EET | Press release
Canoga Perkins and Druid Software showcased their partnership with Canoga Perkins demonstrating Frame Replication and Elimination for Reliability (FRER) at the Winter 2025 Druid Demo Days. This marks a new era of networking for mission critical applications across industries such as mining, industrial automation, and smart manufacturing. FRER is the foremost data protection mechanism delivering unmatched, lossless delivery of mission critical data. Canoga Perkins and Druid created a Private 5G network where SyncMetra protected traffic between the Druid’s Raemis core and the Radio Area Network delivering hitless failover and continuous video traffic. Canoga Perkins is pleased to announce their return to MWC Barcelona in 2026, where they will once again showcase their advanced technical demonstration highlighting FRER and cutting‑edge 5G TSN solutions. The Canoga Perkins team will be on-site to discuss the latest advancements in deterministic networking, including Frame Replication and E
Quantum XChange Advances EUCC Milestone and Enterprise Scalability with Latest Release of Phio TX24.2.2026 14:00:00 EET | Press release
Quantum XChange today announced the latest release of its cryptographic management platform Phio TX® which introduces a new European Union Cybersecurity Certification (EUCC) compliance mode and significant enhancements to its Hive architecture to support massive-scale, distributed deployments. The release marks a critical milestone toward full EUCC validation for Phio TX and reinforces the company’s commitment to meeting rigorous international security standards for customers operating in regulated European markets. EUCC is a European Union–wide certification framework based on Common Criteria (ISO/IEC 15408), providing independent evaluation of Information and Communications Technology (ICT) products against high EU cybersecurity standards. Similar in importance to FIPS validation in the United States, EUCC validation is increasingly critical for organizations handling sensitive or regulated data. Phio TX’s new EUCC compliance mode introduces additional product hardening controls, inc
Compass Pathways to attend TD Cowen 46 th Annual Healthcare Conference in Boston, MA from March 2-4, 202624.2.2026 13:39:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through
Simon-Kucher Selects Navan to Modernize Global Travel Program24.2.2026 12:00:00 EET | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Simon-Kucher, the world’s leading commercial growth and pricing consultancy, as its global travel partner. Simon-Kucher teams will now have access to Navan’s AI-powered travel management platform across more than a dozen markets, including in the North American, European, and APAC regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224745907/en/ Simon-Kucher Selects Navan to Modernize Global Travel Program “Our work is increasingly global, and travel remains essential to how we collaborate with clients and with one another,” said Thomas Wohlan, Director of Travel Management at Simon-Kucher. “To support that at scale, we needed a modern travel platform that brings consistency across countries and simplifies the experience for our teams. Navan enables us to operate more efficiently on a single global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom